Gilead: Purpose 1 Trial

This Gilead clinical trial evaluates investigation PrEP (Pre-exposure Prophylaxis) options, in adolescent girls and young women (AGNYW). This vulnerable population makes up a significant amount of new HIV infections in Sub-Saharan Africa, while simultaneously facing a significant number of socioeconomic hurdles that predispose them to contracting HIV. The PrEp regimens that are being investigated in Purpose 1 include FDA approved: Lenacapivir, and F/TAF or DESCOVY.

For more information on this study visit: PURPOSE Trials for Lenacapavir | HIV Prevention (purposestudies.com)

COVPN 3008 Ubuntu Study

This study investigated the Moderna COVID-19 mRNA vaccine, and evaluated how many vaccine doses were required to protect adults living with HIV and other comorbidities against COVID-19, as they are a vulnerable population group.

For more information on this study visit: https://www.coronaviruspreventionnetwork.org/ubuntu-vaccine-research-study

NC009

NC009 is a TB Alliance clinical trial, aimed at investigating drugs that have the potential to shorten and improve TB treatment. Combinations of TBAJ-876, Pretomanid and Linezolid, as well as the  BPaL regimen are being evaluated on these grounds.

For more information on this study visit: NC-009 | TB Alliance

LIBREXIA STROKE

This clinical trial with Janssen, investigating the efficacy and safety of Milvexian, an oral factor XIa inhibitor, for the prevention and treatment of major thrombotic conditions.

For more information visit: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE – Full Text View – ClinicalTrials.gov

CommuniTB (Gates- MRI TBV02-301)

CommuniTB is a TB Vaccine Trial with the Gate Medical Research Institute (MRI). As the TB epidemic continues to grow in our community, it is essential that we investigate ways to reduce TB infection.

For more information about this study visit: Tuberculosis – The Bill & Melinda Gates Medical Research Institute (gatesmri.org)

Pan-TB (Gates-MRI TBD06-201)

The Pan-TB study, with the Gates Medical Research Institute, is focused on advancing the treatment of all forms of TB, by investigating new drug regimens, with improved tolerability and shorter treatment durations than the current standard of care.

For more information about this study visit: PAN-TB-JDA-Press-Release-August-17-2022.pdf (gatesmri.org)

C4591048- Pfizer

This clinical Trial is evaluating the immune response to an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, in healthy children from the age of 6 months. The aim is to assess safety and tolerability of the vaccine at various dosing regimens.

For more information on this study visit: Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age | Pfizer

C3671032 (MORISOT)- Pfizer

The MORISOT study evaluates the safety and immune activity of the RSV (Respiratory Synctial Virus) vaccine, in infants born to vaccinated mothers. RSV is one of the leading causes of infant mortality and airway diseases. The evaluation of the immune activity will focus on antibodies passed from mother to infant.

For more information in this study visit: Study Details | A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants | ClinicalTrials.gov